文献速递消化道肿瘤与早癌消化内镜

多靶点粪便DNA检测:结直肠癌筛查中的临床性能及对结肠镜检查检出率和质量的影响

Multitarget stool DNA test: clinical performance and impact on yield and quality of colonoscopy for colorectal cancer screening.
PubMed 文献 · Gastrointest Endosc · 2016-11-21

本研究比较了非盲法与盲法结肠镜检查在多靶点粪便DNA(MT-sDNA)阳性患者中的表现。非盲组172例,盲组72例。非盲组腺瘤/无蒂锯齿状息肉检出率更高(70% vs 53%,P=0.013),且结肠镜退镜时间更长(中位19分钟 vs 13分钟,P=0.0001)。结论认为知晓MT-sDNA阳性结果对后续结肠镜检查的诊断产出和质量有有益影响。

要点

  • 非盲组腺瘤/无蒂锯齿状息肉检出率70%,高于盲组53%(P=0.013)。
  • 非盲组中位退镜时间19分钟,长于盲组13分钟(P=0.0001)。
  • 非盲组右侧结肠平坦或稍隆起病变比例40%,高于盲组9%(P=0.0017)。

核心结论

  • 知晓MT-sDNA阳性结果似乎对后续结肠镜检查的诊断产出和质量有有益影响。

研究设计与样本

  • 非盲组为2014年9月1日至2015年9月30日在一家三级中心筛查中MT-sDNA阳性的所有患者,排除超说明书检测者。
  • 盲组为同一中心批准前筛查研究中所有MT-sDNA阳性参与者。
  • 记录详细的结肠镜检查发现和退镜时间。

主要发现

  • 非盲组172例,盲组72例。
  • 非盲组检出腺瘤/无蒂锯齿状息肉的患者比例为70%,盲组为53%(P=0.013)。
  • 非盲组检出进展期肿瘤的患者比例为28%,盲组为21%(P=0.27)。
  • 非盲组检出息肉中位数为2个(IQR 1-4),盲组为1个(IQR 0-2)(P=0.0007)。
  • 非盲组检出息肉中右侧结肠平坦或稍隆起病变的比例为40%,盲组为9%(P=0.0017)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Multitarget stool DNA (MT-sDNA) testing is now approved by the U.S. Food and Drug Administration for average-risk colorectal cancer screening. Trials leading to its approval used blinded colonoscopy as the reference standard. In the postapproval screen setting, the clinical performance and impact of MT-sDNA testing on unblinded colonoscopy has not been described. We measured the impact that knowledge of a positive MT-sDNA test result has on colonoscopy yield and quality. METHODS: The unblinded group comprised all patients with positive MT-sDNA results on screening from September 1, 2014 to September 30, 2015 at a single tertiary center. Off-label test patients were excluded. The blinded group included all MT-sDNA-positive participants in a preapproval screening study from the same center. Detailed colonoscopy findings and withdrawal times were recorded. RESULTS: There were 172 MT-sDNA-positive patients in the unblinded group and 72 in the blinded group. More total adenomatous/sessile serrated polyps (70% vs 53%, P = .013) and advanced neoplasms (28% vs 21%, P = .27) were detected in unblinded than in blinded groups. Median numbers of polyps detected were 2 (IQR, 1-4) and 1 (IQR, 0-2) in unblinded and blinded groups, respectively (P = .0007). Among polyps detected, flat or slightly raised lesions in the right side of the colon were proportionately more frequent with unblinded (40%) than with blinded examinations (9%) (P = .0017). Median withdrawal time was 19 minutes (IQR, 13-29) in the unblinded group compared with 13 minutes (IQR, 10-20) in the blinded group (P = .0001). CONCLUSIONS: Knowledge of a positive MT-sDNA result appears to have a beneficial impact on the diagnostic yield and quality of subsequent colonoscopy.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Johnson DH, Kisiel JB, Burger KN, et al. Multitarget stool DNA test: clinical performance and impact on yield and quality of colonoscopy for colorectal cancer screening. Gastrointest Endosc. 2016. PMID: 27884518. doi:10.1016/j.gie.2016.11.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。